Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors

Article Abstract:

COX-2 inhibitors appear to increase blood clot formation, which could cause a heart attack or stroke. They also have a tendency to increase blood pressure. For this reason, aspirin may be safer in some patients, even though it is more likely to cause gastrointestinal bleeding than COX-2 inhibitors.

Author: Topol, Eric J., Mukherjee, Debabrata, Nissen, Steven E.
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
Complications and side effects, Heart attack, COX-2 inhibitors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial

Article Abstract:

The study aimed to compare the effects of amlodipine or enalapril against placebo on cardiovascular events in patients with coronary artery disease (CAD) is discussed. It is concluded that administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events.

Author: Topol, Eric J., Thompson, Paul D., Nissen, Steven E., Libby, Peter, Tuzcu, E. Murat, Ghali, Magdi, Garza, Dahlia, Berman, Lance, Shi, Harry, Buebendorf, Ethel
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
Science & research, Care and treatment, Research, Coronary heart disease, Heart, Cardiovascular abnormalities, Cardiac patients

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

Article Abstract:

A study is conducted to evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls. Findings reveal that muraglitazar is associated with an excess incidence of the composite end point of death, major adverse cardiovascular events and CHF, and this agent should not be approved to treat diabetes.

Author: Topol, Eric J., Nissen, Steven E., Wolski, Kathy
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2005
United States, Usage, Cardiovascular diseases, Causes of, Type 2 diabetes, Muraglitazar

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Risk factors
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.